Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN)
Jean-Pascal Machiels(Cliniques Universitaires Saint-Luc), Lisa Licitra(University of Milan), Marco Guzzo(Fondazione IRCCS Istituto Nazionale dei Tumori), Paolo Bossi(Humanitas University), Thierry Duprez, Renaud Lhommel(Cliniques Universitaires Saint-Luc), Sandra Schmitz(Cliniques Universitaires Saint-Luc), Ruxandra Coropciuc(KU Leuven), Jessica Menis(University of Verona), Silvana Canevari(Institute of Biomedical Technologies), Michela Lia(Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo), Esther Hauben(Universitair Ziekenhuis Leuven), Marc Lemort(Université Libre de Bruxelles), Nicolas de Saint Aubain(Université Libre de Bruxelles), Catherine Fortpied(European Organisation for Research and Treatment of Cancer), Roberto Bianchi(AOL (United States)), Loris De Cecco(Fondazione IRCCS Istituto Nazionale dei Tumori), Pasquale Quattrone(Fondazione IRCCS Istituto Nazionale dei Tumori), Marie Quiriny(Université Libre de Bruxelles), Y. Liu, Paul M. Clément(Universitair Ziekenhuis Leuven), Flavio Crippa(National Cancer Institute), Yassine Lalami(Université Libre de Bruxelles)
Cited by 43
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
|Cancer|2020|1.3k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994